What is the domestic price of capmatinib in 2024, and can it be reimbursed by medical insurance?

With the advancement of medical technology and the sharing of global medical resources, Capmatinib (Capmatinib, trade name Tabrecta), a targeted treatment drug for non-small cell lung cancer (NSCLC) targeting specific gene mutations, has been approved for marketing in China, bringing new treatment options to many patients. However, for the majority of patients, the price and medical insurance situation are undoubtedly the focus of attention.

1. Price Overview

At present, the domestic price of capmatinib is not widely available, and due to the short time to market, pharmacies are generally out of stock, which makes it difficult to generalize specific price information. However, according to market feedback, capmatinib, as an imported original drug, has a relatively high price, which may bring financial pressure to some patients.

For patients under greater financial pressure, generic drugs may be considered as an alternative. There are currently multiple versions of capmatinib generics on the market, such as the Big Bear version (200mg*56 tablets), the Lucius version (200mg*60 tablets), the combined version (200mg*56 tablets), and the elemental version (200mg*56 tablets). These generic drugs are similar to the original drugs in terms of ingredients and specifications, but are more affordable. Specifically, the price of a box of the Big Bear version and the United version is about more than 3,000 yuan, the Lucius version is slightly lower, about 3,000 yuan, and the price of the element version is slightly higher, with a box of medicine selling for about 4,000 yuan.

2. Medical insurance situation

It is worth noting that capmatinib is not yet included in the national medical insurance catalog, which means that patients cannot enjoy medical insurance reimbursement when using this drug and need to bear the full cost of the drug out of their own pocket.

3. Suggestions on purchasing medicines

Faced with the high prices of original drugs and the choice of generic drugs, patients should make rational decisions based on their own financial situation and doctor's advice. At the same time, no matter which drug you choose, you should make sure to purchase it through formal channels to avoid encountering fake and shoddy products.

In addition, patients should pay close attention to their physical condition while using capmatinib. If they experience any discomfort or side effects, they should seek medical treatment in time and inform the doctor of the drug they are using. At the same time, patients are advised to pay attention to the dynamics of national medical insurance policies in order to enjoy more medical benefits in the future.

To sum up, capmatinib, as a targeted treatment drug for non-small cell lung cancer targeting specific gene mutations, has been approved for marketing in China, but it is expensive and has not yet been included in the medical insurance catalog. Patients should make choices based on their own circumstances when using them, and ensure that they purchase drugs through formal channels.